Page last updated: 2024-10-22

am 251 and Pain

am 251 has been researched along with Pain in 44 studies

AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
"Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization."7.78Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. ( Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV, 2012)
"N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents."5.34New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007)
"It is aimed to investigate the possible contribution of cannabinoid system that supresses the nociceptive process by the activation of CB1 and CB2 receptors in central and peripheral levels of pain pathways, to the analgesic activity of protocatechuic acid."3.91Cannabinoid system involves in the analgesic effect of protocatechuic acid. ( Arslan, R; Bektas, N; Dikmen, DY; Okcay, Y, 2019)
"Chemical stimulation of the lateral hypothalamus (LH) with carbachol induces antinociception which is antagonized by blockade of orexin receptors in some pain modulatory sites in the tail-flick test."3.83Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats. ( Esmaeili, MH; Ezzatpanah, S; Haghparast, A; Reisi, Z, 2016)
"The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials."3.81A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. ( Binkowski, M; Czaja, M; Di Marzo, V; Kolosowska, N; Makuch, W; Malek, N; Morera, E; Mrugala, M; Przewlocka, B; Starowicz, K, 2015)
"Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization."3.78Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. ( Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV, 2012)
"In this study we analyzed the mechanisms underlying celecoxib-induced analgesia in a model of inflammatory pain in rats, using the intracerebroventricular (i."3.78Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system. ( Bakhle, YS; Camêlo, VM; Dos Reis, WG; Faraco, A; Francischi, JN; Paiva-Lima, P; Rezende, RM, 2012)
"Neurotensin modulates pain via its actions within descending analgesic pathways which include brain regions such as the midbrain periaqueductal grey (PAG)."3.75Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey. ( Kawahara, H; Mitchell, VA; Vaughan, CW, 2009)
"This study shows that electroacupuncture increases the anandamide level in inflammatory skin tissues, and CB2 receptors contribute to the analgesic effect of electroacupuncture in a rat model of inflammatory pain."3.75Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats. ( Chen, L; Li, F; Li, M; Li, YH; Pan, HL; Qiu, Y; Shi, J; Wang, L; Zhang, J, 2009)
"Cannabinoids, such as anandamide, are involved in pain transmission."3.74AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain. ( Bianchi, R; Borsani, E; Labanca, M; Rodella, LF, 2007)
"Stress contributes to major depressive disorder (MDD) and chronic pain, which affect a significant portion of the global population, but researchers have not clearly determined how these conditions are initiated or amplified by stress."1.62mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress. ( Han, J; Huang, M; Luo, L; Ma, X; Shi, H; Su, C; Wang, A; Wang, H; Wang, W; Wu, K; Xu, T; Xu, X; Yuan, T, 2021)
"Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients."1.56Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020)
"Pain was induced by formalin (2%) injection into the hind paw."1.42Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. ( Ali Reza, M; Azizi, H; Mirnajafi-Zadeh, J; Mohammad-Pour Kargar, H; Semnanian, S, 2015)
"Substance P release was measured as neurokinin 1 (NK1) receptor internalization in lamina I neurons."1.36Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. ( Chen, W; Lao, L; Marvizón, JC; Zhang, G, 2010)
"Cholestasis is associated with increased activity of the endogenous opioid system that results in analgesia."1.35The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis. ( Hasanein, P, 2009)
"N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents."1.34New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007)
"Mechanical allodynia and thermal hyperalgesia were evaluated in 46 rats allocated to receive: (1) Vehicle (before surgery)-Vehicle (after surgery); (2) Vehicle-WIN55,212-2; (3) WIN55,212-2-Vehicle; (4) WIN55,212-2-WIN55,212-2; (5) AM251+vehicle; (6) AM251+WIN55,212-2; (7) AM630+vehicle; (8) AM630+WIN55,212-2; (9) Sham receiving vehicle; and (10) Sham receiving WIN55,212-2."1.34Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. ( Beaulieu, P; Dani, M; Desroches, J; Guindon, J, 2007)
" The dose-response curve of i."1.32Topical cannabinoid antinociception: synergy with spinal sites. ( Akar, A; Bilgin, F; Dogrul, A; Gul, H; Guzeldemir, E; Yildiz, O, 2003)
"Anandamide was able to inhibit dural blood vessel dilation brought about by electrical stimulation by 50%, calcitonin gene-related peptide (CGRP) by 30%, capsaicin by 45%, and nitric oxide by 40%."1.32Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. ( Akerman, S; Goadsby, PJ; Kaube, H, 2004)
"WIN 55,212-2 attenuated both heat and mechanical hyperalgesia dose-dependently."1.32Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. ( Johanek, LM; Simone, DA, 2004)

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (38.64)29.6817
2010's23 (52.27)24.3611
2020's4 (9.09)2.80

Authors

AuthorsStudies
Ortar, G1
Cascio, MG1
De Petrocellis, L1
Morera, E2
Rossi, F1
Schiano-Moriello, A1
Nalli, M1
de Novellis, V1
Woodward, DF1
Maione, S1
Di Marzo, V2
Crivelaro do Nascimento, G1
Ferrari, DP1
Guimaraes, FS1
Del Bel, EA1
Bortolanza, M1
Ferreira-Junior, NC1
Rodrigues, FF1
Morais, MI1
Melo, ISF1
Augusto, PSA1
Dutra, MMGB1
Costa, SOAM1
Costa, FC1
Goulart, FA1
Braga, AV1
Coelho, MM1
Machado, RR1
Godoi, MM1
Junior, HZ1
da Cunha, JM1
Zanoveli, JM1
Xu, X1
Wu, K1
Ma, X1
Wang, W1
Wang, H1
Huang, M1
Luo, L1
Su, C1
Yuan, T1
Shi, H1
Han, J1
Wang, A1
Xu, T1
Wang, P1
Zheng, T1
Zhang, M1
Xu, B1
Zhang, R1
Zhang, T1
Zhao, W1
Shi, X1
Zhang, Q1
Fang, Q2
Rea, K2
McGowan, F1
Corcoran, L1
Roche, M2
Finn, DP2
Giorno, TBS1
Moreira, IGDS1
Rezende, CM1
Fernandes, PD1
Dikmen, DY1
Okcay, Y1
Arslan, R1
Bektas, N1
Olango, WM1
Harhen, B1
Kerr, DM1
Galligan, R1
Fitzgerald, S1
Moore, M1
Elmas, P1
Ulugol, A1
Anderson, WB1
Gould, MJ1
Torres, RD1
Mitchell, VA3
Vaughan, CW3
Petrenko, AB1
Yamazaki, M1
Sakimura, K1
Kano, M1
Baba, H1
Malek, N1
Mrugala, M1
Makuch, W1
Kolosowska, N1
Przewlocka, B1
Binkowski, M1
Czaja, M1
Starowicz, K1
Mohammad-Pour Kargar, H1
Azizi, H1
Mirnajafi-Zadeh, J1
Ali Reza, M1
Semnanian, S1
Carey, LM1
Slivicki, RA1
Leishman, E1
Cornett, B1
Mackie, K2
Bradshaw, H1
Hohmann, AG1
Esmaeili, MH2
Reisi, Z2
Ezzatpanah, S2
Haghparast, A3
Sagar, DR1
Kendall, DA2
Chapman, V2
Kawahara, H1
Chen, L1
Zhang, J1
Li, F1
Qiu, Y1
Wang, L1
Li, YH1
Shi, J1
Pan, HL1
Li, M1
Hasanein, P1
Zhang, G1
Chen, W1
Lao, L1
Marvizón, JC1
Curto-Reyes, V1
Llames, S1
Hidalgo, A1
Menéndez, L1
Baamonde, A1
Staniaszek, LE1
Norris, LM1
Barrett, DA1
Ebrahimzadeh, M1
Han, ZL1
Li, N1
Wang, ZL1
He, N1
Wang, R1
Ho, YC1
Lee, HJ1
Tung, LW1
Liao, YY1
Fu, SY1
Teng, SF1
Liao, HT1
Chiou, LC1
Negrete, R1
Hervera, A1
Leánez, S1
Martín-Campos, JM1
Pol, O1
Naderi, N1
Majidi, M1
Mousavi, Z1
Khoramian Tusi, S1
Mansouri, Z1
Khodagholi, F1
Tumati, S1
Largent-Milnes, TM1
Keresztes, A1
Ren, J1
Roeske, WR1
Vanderah, TW1
Varga, EV1
Rezende, RM1
Paiva-Lima, P1
Dos Reis, WG1
Camêlo, VM1
Faraco, A1
Bakhle, YS1
Francischi, JN1
Dogrul, A1
Gul, H1
Akar, A1
Yildiz, O1
Bilgin, F1
Guzeldemir, E1
Akerman, S1
Kaube, H1
Goadsby, PJ1
Johanek, LM1
Simone, DA1
Antoniou, K1
Galanopoulos, A1
Vlachou, S1
Kourouli, T1
Nahmias, V1
Thermos, K1
Panagis, G1
Daifoti, Z1
Marselos, M1
Papahatjis, D1
Spyraki, C1
Guindon, J2
De Léan, A1
Beaulieu, P2
Liu, C1
Walker, JM1
Borsani, E1
Labanca, M1
Bianchi, R1
Rodella, LF1
Desroches, J1
Dani, M1
Greenwood, R1
Jayamanne, A1
Schuelert, N1
McDougall, JJ1
da Fonseca Pacheco, D1
Klein, A1
de Castro Perez, A1
da Fonseca Pacheco, CM1
de Francischi, JN1
Duarte, ID1
Mallet, C1
Daulhac, L1
Bonnefont, J1
Ledent, C1
Etienne, M1
Chapuy, E1
Libert, F1
Eschalier, A1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269]Phase 230 participants (Anticipated)Interventional2020-04-20Recruiting
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms[NCT05142267]120 participants (Anticipated)Interventional2022-03-02Recruiting
An Open-label, Single-dose, Pharmacokinetic Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Orthodontic Pain[NCT05844995]Phase 130 participants (Anticipated)Interventional2023-09-13Recruiting
A Full-Factorial, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Efficacy and Safety Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen, and Naproxen Sodium in Postoperative Dental Pain[NCT05761574]Phase 3440 participants (Anticipated)Interventional2023-05-22Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

44 other studies available for am 251 and Pain

ArticleYear
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
    Journal of medicinal chemistry, 2007, Dec-27, Volume: 50, Issue:26

    Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Biphenyl Compounds; Brain; Calcium; Carbama

2007
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
    Neuropharmacology, 2020, Volume: 163

    Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox

2020
Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.
    Inflammopharmacology, 2020, Volume: 28, Issue:2

    Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Behavior, Animal; Carrageenan;

2020
Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
    Pharmacology, biochemistry, and behavior, 2020, Volume: 194

    Topics: Analgesics, Opioid; Animals; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Agonists; Can

2020
mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress.
    Molecular neurobiology, 2021, Volume: 58, Issue:10

    Topics: Animals; Cannabinoid Receptor Antagonists; Chronic Disease; Depressive Disorder, Major; Endocannabin

2021
Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
    Brain research bulletin, 2018, Volume: 139

    Topics: Acetic Acid; Analgesics; Animals; Area Under Curve; Disease Models, Animal; Dose-Response Relationsh

2018
The prefrontal cortical endocannabinoid system modulates fear-pain interactions in a subregion-specific manner.
    British journal of pharmacology, 2019, Volume: 176, Issue:10

    Topics: Animals; Behavior, Animal; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Conditioning, Ps

2019
New
    Scientific reports, 2018, 07-03, Volume: 8, Issue:1

    Topics: Analgesics; Animals; Behavior, Animal; Capsaicin; Coffee; Disease Models, Animal; Female; Formaldehy

2018
Cannabinoid system involves in the analgesic effect of protocatechuic acid.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2019, Volume: 27, Issue:2

    Topics: Acetic Acid; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxyb

2019
Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats.
    Pain, 2013, Volume: 154, Issue:4

    Topics: Amygdala; Analgesia; Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Conditioning, Psycho

2013
Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.
    Journal of neural transmission (Vienna, Austria : 1996), 2013, Volume: 120, Issue:11

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazines; Cannabinoid Receptor Ago

2013
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.
    Neuropharmacology, 2014, Volume: 81

    Topics: Amidohydrolases; Analgesics; Analysis of Variance; Animals; Arthritis, Experimental; Benzamides; Ben

2014
Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol.
    Behavioural brain research, 2014, Sep-01, Volume: 271

    Topics: Animals; Arachidonic Acids; Benzodioxoles; Cannabinoid Receptor Modulators; Endocannabinoids; Glycer

2014
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
    Pain, 2015, Volume: 156, Issue:5

    Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides

2015
Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors.
    Brain research, 2015, Oct-22, Volume: 1624

    Topics: Analgesics; Analysis of Variance; Animals; Benzoxazoles; Carrier Proteins; Dose-Response Relationshi

2015
A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
    Molecular pain, 2016, Volume: 12

    Topics: Acrylamides; Amidohydrolases; Analgesia; Animals; Arachidonic Acid; Bridged Bicyclo Compounds, Heter

2016
Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats.
    European journal of pain (London, England), 2016, Volume: 20, Issue:10

    Topics: Animals; Benzoxazoles; Carbachol; Disease Models, Animal; Hypothalamic Area, Lateral; Male; Microinj

2016
Role of orexin-2 and CB1 receptors within the periaqueductal gray matter in lateral hypothalamic-induced antinociception in rats.
    Behavioural pharmacology, 2017, Volume: 28, Issue:1

    Topics: Animals; Carbachol; Disease Models, Animal; Dose-Response Relationship, Drug; Hypothalamic Area, Lat

2017
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain.
    British journal of pharmacology, 2008, Volume: 155, Issue:8

    Topics: Amidohydrolases; Analgesia; Animals; Benzamides; Carbamates; Carrageenan; Disease Models, Animal; In

2008
Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey.
    The Journal of physiology, 2009, Jun-01, Volume: 587, Issue:Pt 11

    Topics: Adamantane; Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Excitatory Amino Acid Antago

2009
Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats.
    The journal of pain, 2009, Volume: 10, Issue:7

    Topics: Animals; Arachidonic Acids; Chromatography, High Pressure Liquid; Electroacupuncture; Endocannabinoi

2009
The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis.
    Neuroscience letters, 2009, Oct-25, Volume: 462, Issue:3

    Topics: Animals; Arachidonic Acids; Biological Transport; Camphanes; Cannabinoid Receptor Modulators; Choles

2009
Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization.
    The European journal of neuroscience, 2010, Volume: 31, Issue:2

    Topics: Animals; Capsaicin; Electric Stimulation; GABA-B Receptor Antagonists; Injections, Spinal; Male; Mor

2010
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.
    British journal of pharmacology, 2010, Volume: 160, Issue:3

    Topics: Analgesics; Animals; Bone Neoplasms; Camphanes; Cannabinoids; Cell Line, Tumor; Disease Models, Anim

2010
Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids.
    British journal of pharmacology, 2010, Volume: 160, Issue:3

    Topics: Animals; Cannabinoid Receptor Modulators; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response

2010
Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.
    Brain research, 2011, Oct-28, Volume: 1420

    Topics: Analgesics; Analysis of Variance; Animals; Area Under Curve; Benzoxazines; Cannabinoid Receptor Agon

2011
Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
    Neuropharmacology, 2012, Volume: 62, Issue:2

    Topics: Analgesia; Analgesics; Animals; Benzoxazines; Indoles; Male; Mice; Morpholines; Naloxone; Naphthalen

2012
Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2011, Oct-12, Volume: 31, Issue:41

    Topics: Analysis of Variance; Animals; Animals, Newborn; Arachidonic Acids; Benzoxazines; Benzoxazoles; Biph

2011
The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids.
    PloS one, 2011, Volume: 6, Issue:10

    Topics: Analgesics; Analgesics, Opioid; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagon

2011
The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats.
    Neurochemical research, 2012, Volume: 37, Issue:4

    Topics: Amides; Animals; Drug Interactions; Endocannabinoids; Ethanolamines; Injections, Spinal; Interleukin

2012
Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.
    Journal of neuroimmunology, 2012, Volume: 244, Issue:1-2

    Topics: Analgesics; Analgesics, Opioid; Animals; Cannabinoids; Hyperalgesia; Indoles; Inflammation; Interleu

2012
Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system.
    Pharmacology, 2012, Volume: 89, Issue:3-4

    Topics: Analgesics; Animals; Carrageenan; Celecoxib; Central Nervous System; Cyclooxygenase 2; Cyclooxygenas

2012
Topical cannabinoid antinociception: synergy with spinal sites.
    Pain, 2003, Volume: 105, Issue:1-2

    Topics: Administration, Topical; Analgesics; Animals; Benzoxazines; Cannabinoids; Dose-Response Relationship

2003
Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 309, Issue:1

    Topics: Animals; Arachidonic Acids; Blood Pressure; Calcitonin Gene-Related Peptide; Capsaicin; Electric Sti

2004
Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
    Pain, 2004, Volume: 109, Issue:3

    Topics: Animals; Benzoxazines; Burns; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disea

2004
Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3.
    Behavioural pharmacology, 2005, Volume: 16, Issue:5-6

    Topics: Animals; Behavior, Animal; Binding, Competitive; Cannabinoids; Catalepsy; Cell Membrane; Cerebral Co

2005
Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain.
    Pain, 2006, Volume: 121, Issue:1-2

    Topics: Acute Disease; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic A

2006
Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
    Journal of neurophysiology, 2006, Volume: 96, Issue:6

    Topics: Analgesics; Animals; Behavior, Animal; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Canna

2006
AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain.
    Brain research, 2007, Jun-04, Volume: 1152

    Topics: Animals; Arachidonic Acids; Capsaicin; Endocannabinoids; Immunohistochemistry; Indoles; Inflammation

2007
Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
    European journal of pharmacology, 2007, Jul-30, Volume: 568, Issue:1-3

    Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Hyperalgesia; Indoles; Male; Morpholines; Naphthale

2007
Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
    Clinical and experimental pharmacology & physiology, 2007, Volume: 34, Issue:11

    Topics: Analgesics; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carrier Proteins; Disease M

2007
Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:1

    Topics: Afferent Pathways; Anilides; Animals; Arachidonic Acids; Cinnamates; Knee Joint; Male; Nociceptors;

2008
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
    British journal of pharmacology, 2008, Volume: 154, Issue:5

    Topics: Amidohydrolases; Analgesics, Opioid; Animals; Arachidonic Acids; Benzamides; Benzomorphans; Cannabin

2008
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
    Pain, 2008, Sep-30, Volume: 139, Issue:1

    Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug

2008
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
    Pain, 2008, Sep-30, Volume: 139, Issue:1

    Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug

2008
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
    Pain, 2008, Sep-30, Volume: 139, Issue:1

    Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug

2008
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
    Pain, 2008, Sep-30, Volume: 139, Issue:1

    Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug

2008